Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
02 nov. 2023 09h05 HE
|
Agios Pharmaceuticals, Inc.
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support...
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
02 nov. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease – – Completed Enrollment in Phase 3 ACTIVATE-KidsT Pediatric Study of Mitapivat in PK...
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
19 oct. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
29 août 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
03 août 2023 06h35 HE
|
Agios Pharmaceuticals, Inc.
Announced Positive Results from Phase 2 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease; On Track to Enroll First Patient in Phase 3 Portion of the Study in Q4 2023 ...
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
03 août 2023 06h30 HE
|
Agios Pharmaceuticals, Inc.
– Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera – – Agreement Combines Agios’ Scientific Expertise and Capabilities in Rare Hematologic Diseases...
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
13 juil. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
26 juin 2023 06h30 HE
|
Agios Pharmaceuticals, Inc.
– Study’s Primary Efficacy Endpoint Achieved, with 46.2% of Patients in the 50 mg BID Mitapivat Arm and 50.0% of Patients in the 100 mg BID Mitapivat Arm Achieving a Hemoglobin Response, Compared to...
Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023
05 juin 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Appoints Catherine Owen to Board of Directors
25 mai 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
– John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE...